SCHOTT Pharma AG & Co. KGaA : H1 results in line with preliminary figures - 2024 guidance confirmed
>H1 was strongly impacted by FX headwinds - SCHOTT Pharma’s final H1 figures were in line with prel. results, which were published on 14 May 2024. In H1 2024, the company’s revenues grew by 9% to € 466m at constant currencies (H1 2023: € 449m). The company’s EBITDA increased slightly (+2% at cc / -11% reported) compared to the prior year despite ramp-up cost from the continued investments in capacity expansion. Revenues and EBITDA on a reported basis were impacted by ...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.